Actively Recruiting
Randomized, Observer-blind, Placebo-controlled Study to Evaluate rVSV94G-SUDV-GP Vaccine Safety and Immune Response in Healthy Adults
Led by International AIDS Vaccine Initiative · Updated on 2026-09-21
112
Participants Needed
3
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a Phase 1 clinical trial to evaluate the safety and immune response of the rVSV94G-SUDV-GP vaccine designed to prevent Sudan Virus Disease in healthy adults aged 18 to 50 years. This study uses a randomized, observer-blind, placebo-controlled, dose-escalation design to carefully assess different dose levels of the vaccine. The trial is led by the International AIDS Vaccine Initiative and involves close monitoring for safety and vaccine response.
CONDITIONS
Brief Title
A Clinical Study to Investigate the Safety and Immunogenicity of rVSV∆G-SUDV-GP, a Sudan Virus (SUDV) Vaccine for the Prevention of SUDV Disease in Adults in Good General Health
Research Team
J
Johannes Beeslaar, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here